210532-24-4

Usage

General Description

2,3-difluorobenzene-1-sulfonyl chloride is a chemical compound with the molecular formula C6H3ClF2O2S. It is a sulfonyl chloride derivative of 2,3-difluorobenzene, and it is commonly used as a reagent in organic synthesis. Sulfonyl chlorides are important building blocks in organic chemistry and are widely used in the production of pharmaceuticals, agrochemicals, and materials. 2,3-difluorobenzene-1-sulfonyl chloride is a versatile reagent with the ability to form carbon-sulfur, carbon-oxygen, and carbon-nitrogen bonds, making it valuable in the synthesis of diverse functional molecules. It is also known for its strong electrophilic nature, which makes it a potent acylating agent in various chemical reactions.

Upstream product

• 7719-09-7 thionyl chloride 
• 1489175-55-4 C₆H₃F₂N₂⁽¹⁺⁾*Cl^(1-) 
• 4519-40-8 2,3-difluoroanilline 

Downstream Products

• 1204573-14-7 2-cyclopropylamino-3-fluorobenzenesulphonamide 
• 1133122-99-2 2,3-difluorobenzenesulphonamide 
• 1161943-95-8 2,3-Difluoro-N-(4-fluoro-2-sulfamoyl-phenyl)benzenesulfonamide 
• 1161943-94-7 2,3-Difluoro-N-(2-sulfamoylphenyl)benzenesulfonamide 
• 1055306-50-7 tert-butyl ({1-[(2,3-difluorophenyl)sulfonyl]-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl}methyl)methylcarbamate 

Relevant academic research and scientific papers

Thermodynamic characterization of new positive allosteric modulators binding to the glutamate receptor A2 ligand-binding domain: Combining experimental and computational methods unravels differences in driving forces

Positive allosteric modulation of the ionotropic glutamate receptor GluA2 presents a potential treatment of cognitive disorders, for example, Alzheimer's disease. In the present study, we describe the synthesis, pharmacology, and thermodynamic studies of a series of monofluoro-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides. Measurements of ligand binding by isothermal titration calorimetry (ITC) showed similar binding affinities for the modulator series at the GluA2 LBD but differences in the thermodynamic driving forces. Binding of 5c (7-F) and 6 (no-F) is enthalpy driven, and 5a (5-F) and 5b (6-F) are entropy driven. For 5d (8-F), both quantities were equal in size. Thermodynamic integration (TI) and one-step perturbation (OSP) were used to calculate the relative binding affinity of the modulators. The OSP calculations had a higher predictive power than those from TI, and combined with the shorter total simulation time, we found the OSP method to be more effective for this setup. Furthermore, from the molecular dynamics simulations, we extracted the enthalpies and entropies, and along with the ITC data, this suggested that the differences in binding free energies are largely explained by the direct ligand-surrounding enthalpies. Furthermore, we used the OSP setup to predict binding affinities for a series of polysubstituted fluorine compounds and monosubstituted methyl compounds and used these predictions to characterize the modulator binding pocket for this scaffold of positive allosteric modulators.

BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES

The invention relates to compounds of formula (XVI): (XVI) or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein Y2, Z, L1, R9, R10, m and u are defined herein. These compounds ar

COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES

The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.

STEROID SPARING AGENTS AND METHODS OF USING SAME

This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.

Nitromethylthiobenzene derivatives as inhibitors of aldose reductase

The invention concerns novel compound of general formula (1) in which: P, T1, T2, X and n are as defined in claim 1, their tautomeric forms, and their additive salts with pharmaceutically acceptable bases. The invention also concerns methods for preparing these compounds and their applications as medicines. These compounds inhibit the aldose reductase enzyme and can be used in the treatment or prevention of peripheral and autonomous neurological diabetic complications, renal and ocular disorders such as cataract and retinopathy.

HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS

Disclosed are compounds which bind 4 integrins, where the 4integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by 4integrins, where the 4 integrin is preferably VLA-4. Su

Polymer electrolyte and process for producing the same

A polymer electrolyte having, in a main chain, a structural unit represented by the following formula (1):-[Ar1-(SO2-N-(X+)-SO2-Ar2)m-SO2-N-(X+)-SO2-Ar1-O]- wherein Ar1 and Ar2 independently represent a divalent aromatic groups, m represents an integer of 0 to 3, and X+ represents an ion selected from hydrogen ion, an alkali metal ion and ammonium ion, which is excellent in proton conductivity, thermal resistance and strength. The polymer electrolyte is soluble in solvents and has excellent film forming property and recycling efficiency.